# US 2016/0250266 A1 · Pure filamentous bacteriophage and methods of producing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250266 A1
- Document ID: US20160250266A1
- Status: Published application
- Kind: A1
- Application number: 14/964,858
- Filed: 2015-12-10
- Published: 2016-09-01
- Earliest claimed: 2011-08-05
- Assignees: NeuroPhage Pharmaceuticals, Inc.
- Applicants: NeuroPhage Pharmaceuticals, Inc.
- Inventors: Jason Wright; Antony Hitchcock; Frank Sugar; Tim Davies; Shreekant Adhikari; Nanda Menon; Quentin Florence
- Web page: https://patentgrep.com/patent/US20160250266A1

## CPC

- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/14151: Methods of production or purification of viral material
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.

## Claims

### Claim 1

A pharmaceutical composition comprising wild-type filamentous bacteriophage or filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface, said composition comprising less than 1×10−10 endotoxin units per filamentous bacteriophage; and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than 1×10−11 endotoxin units per filamentous bacteriophage.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than 1×10−12 endotoxin units per filamentous bacteriophage.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than 1×10−13 endotoxin units per filamentous bacteriophage.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, comprising less than 5×10−14 endotoxin units per filamentous bacteriophage.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is a liquid composition.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, having at least 4×1017 filamentous bacteriophage.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1 wherein the filamentous bacteriophage are M13.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1 in a solid form.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, formulated into tablets, granulates, nano-particles, nano-capsule micro-capsules, micro-tablets, pellets, or powders.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1 formulated into a single dosage form.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the single dosage form is contained in a vial.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the single dosage form is contained in an infusion bag or pump reservoir.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the single dosage form is contained in one or more tablets or capsules.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, comprising an amount of endotoxin that when administered to a human provides less than 5.0 endotoxin units per kilogram body weight per dose.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, comprising an amount of endotoxin that when administered to a human provides less than 0.2 endotoxin units per kilogram body weight per dose.

### Claim 17

A method of reducing the amount of amyloid plaque in a patient suffering from a plaque-forming disease, comprising the step of administering to the patient a pharmaceutical composition comprising filamentous bacteriophage; and a pharmaceutically acceptable carrier, wherein the composition comprises less than 1×10−10 endotoxin units per filamentous bacteriophage.

### Claim 18 (depends on 17)

The method of claim 17, wherein the filamentous bacteriophage is selected from wild-type filamentous bacteriophage or filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface.

### Claim 19 (depends on 17)

The method of claim 17, wherein the plaque-forming disease is selected from Alzheimer's disease, SAA amyloidosis, hereditary Icelandic Syndrome, senility, multiple myeloma, Kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia (FFI), scrapie, bovine spongiform encephalitis (BSE), Parkinson's Disease, Amyotrophic lateral sclerosis/parkinsonism-dementia complex, Argyrophilic grain dementia, Corticobasal degeneration, Dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, Frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, Myotonic dystrophy, Niemann-Pick disease type C, Non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease, Postencephalitic parkinsonism, Progressive subcortical gliosis, Progressive supranuclear palsy, Subacute sclerosing panencephalitis, and Tangle only dementia.

### Claim 20 (depends on 19)

The method of claim 19, wherein the plaque-forming disease is selected from early onset Alzheimer's disease, late onset Alzheimer's disease or pre-symptomatic Alzheimer's disease.
